Source: India Times

New Delhi: Union Minister of State for Chemicals and Fertilizers, Mansukh Mandaviya said that the production of Hydroxychloroquine is more than the requirement in India, hence the government has lifted export restrictions on it.

“When the COVID crisis started we had two units making Hydroxychloroquine, now we have 12 and production is more than the requirement. Hence, the Government of India lifted export restrictions on it. Manufacturers have to sell 20 per cent in domestic market, the rest can be exported,”

Union Minister of State for Chemicals and Fertilizers, Mansukh Mandaviy

He shared that Hydroxychloroquine was banned when nationwide lockdown was announced earlier as at that time only two manufacturing units were producing 50 lakh tablets daily.

But today, 12 manufacturing units in the country are producing 1.5 crore tablets daily, he added.

“In such a situation, the Government of India has decided to lift the ban on Hydroxychloroquine, its APIs and formulations. All have to be sold 20 per cent in domestic market so that there is no shortage of medicine in the country,” Mandaviya stated and added that additional production can be exported in the global market.

Union Minister Sadananda Gowda had on Wednesday tweeted, “Department of Pharmaceuticals has approved the lifting of ban on Export of Hydroxychloroquine API as well as formulations. Manufacturers except SEZ/EOU Units have to supply 20 per cent production in the domestic market. DGFT has been asked to issue formal notification in this regard.”

Related: Hydroxychloroquine Market Size Worth Around US$ 6 Bn by 2027

Turkish company manufactures hydroxychloroquine drug

Syrian Labs Churn Out Anti-Malarial Drug

Manufacturer to move hydroxychloroquine production to the UK to avoid shortage

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »